ATE419277T1 - Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen - Google Patents

Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen

Info

Publication number
ATE419277T1
ATE419277T1 AT04764918T AT04764918T ATE419277T1 AT E419277 T1 ATE419277 T1 AT E419277T1 AT 04764918 T AT04764918 T AT 04764918T AT 04764918 T AT04764918 T AT 04764918T AT E419277 T1 ATE419277 T1 AT E419277T1
Authority
AT
Austria
Prior art keywords
factor
effects
specific antibodies
ligands
exhibit
Prior art date
Application number
AT04764918T
Other languages
German (de)
English (en)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419277(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of ATE419277T1 publication Critical patent/ATE419277T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04764918T 2003-09-12 2004-09-07 Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen ATE419277T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity

Publications (1)

Publication Number Publication Date
ATE419277T1 true ATE419277T1 (de) 2009-01-15

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764918T ATE419277T1 (de) 2003-09-12 2004-09-07 Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen

Country Status (9)

Country Link
US (1) US7297336B2 (enExample)
EP (1) EP1660536B1 (enExample)
JP (1) JP4887148B2 (enExample)
AT (1) ATE419277T1 (enExample)
AU (1) AU2004271706B2 (enExample)
CA (1) CA2538895A1 (enExample)
DE (1) DE602004018788D1 (enExample)
ES (1) ES2320665T3 (enExample)
WO (1) WO2005025615A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (en) * 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
HRP20180421T1 (hr) 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
ES2668455T3 (es) * 2012-09-28 2018-05-18 Chugai Seiyaku Kabushiki Kaisha Método para evaluar la reacción de coagulación sanguínea
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
EP3116544A4 (en) 2014-03-11 2017-08-23 The Board of Trustees of the Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
TW202402326A (zh) 2016-04-28 2024-01-16 日商中外製藥股份有限公司 含抗體製劑
RU2022108606A (ru) * 2016-05-16 2022-04-11 Такеда Фармасьютикал Компани Лимитед Антитела к фактору ix padua
EP3509637B1 (en) 2016-09-06 2024-11-27 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CA3034105A1 (en) * 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
MY204641A (en) 2017-09-29 2024-09-06 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
CR20240273A (es) 2017-11-01 2024-08-27 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
PE20211399A1 (es) 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
LT3723858T (lt) * 2018-12-21 2022-02-10 Kymab Limited Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę
CN115052898B (zh) 2020-01-30 2025-09-16 诺和诺德股份有限公司 双特异性因子viii模拟抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2152953T3 (es) 1992-08-27 2001-02-16 Sanquin Bloedvoorziening Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
JP2002510321A (ja) 1997-07-03 2002-04-02 スミスクライン・ビーチャム・コーポレイション 抗−第ＩＸ因子 Ｆａｂフラグメントの結晶構造およびペプチド模倣物デザインのための使用方法
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
KR100900166B1 (ko) * 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도

Also Published As

Publication number Publication date
CA2538895A1 (en) 2005-03-24
WO2005025615A3 (en) 2005-06-02
JP2007504812A (ja) 2007-03-08
US20050058640A1 (en) 2005-03-17
AU2004271706A1 (en) 2005-03-24
US7297336B2 (en) 2007-11-20
ES2320665T3 (es) 2009-05-27
WO2005025615A2 (en) 2005-03-24
AU2004271706B2 (en) 2010-09-02
EP1660536A2 (en) 2006-05-31
JP4887148B2 (ja) 2012-02-29
DE602004018788D1 (de) 2009-02-12
EP1660536B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ATE419277T1 (de) Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
EA200700225A1 (ru) Аналоги тетрапептида
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
SE0302139D0 (sv) Novel compounds
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
BRPI0412989A (pt) combinação farmacêutica útil para mobilização de célula-tronco
NO20055741L (no) Nye kjemiske forbindelser
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE514718T1 (de) Peptabody für krebsbehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1660536

Country of ref document: EP